Dexamethasone disrupts cytoskeleton organization and migration of T47D human breast cancer cells by modulating the AKT/mTOR/RhoA pathway

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 23, 2014, Pages 10245-10250

  Meng, Xian Guo ^a,b   Yue, Shou Wei ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Medical College   (China)

Author keywords

Cell migration; Cytoskeleton; Dexamethasone; T47D breast cancer cells

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DEXAMETHASONE; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

BREAST TUMOR; CELL MOTION; CELL SURVIVAL; CYTOSKELETON; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CYTOSKELETON; DEXAMETHASONE; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84921813216     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.23.10245     Document Type: Article

References (44)

1. Alain T, Morita M, Fonseca BD, et al (2012). eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res, 72, 6468-76.
2. Altomare DA, Wang HQ, Skele KL, et al (2004). AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene, 23, 5853-7.
3. Alvarez M, Roman E, Santos ES, Raez LZ (2007). New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther, 7, 1423-37.
4. Ang C, Jhaveri K, Patel D, et al (2013). Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases. Breast J, 19, 96-9.
5. Armstrong K, Eisen A, Weber B (2000). Assessing the risk of breast cancer. N Engl J Med, 342, 564-71.
6. Atif F, Yousuf S, Stein DG (2014). Anti-tumor effects of progesterone in human glioblastoma multiforme: Role of PI3K/Akt/mTOR signaling. J Steroid Biochem Mol Biol, [Epub ahead of print].
7. Banciu M, Schiffelers RM, Metselaar JM, Storm G (2008). Utility of targeted glucocorticoids in cancer therapy. J Liposome Res, 18, 47-57.
8. Cuzick J, DeCensi A, Arun B, et al (2011). Preventive therapy for breast cancer: a consensus statement. Lancet Oncol, 12, 496-503.
9. Frankfurt O, Rosen ST (2004). Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol, 16, 553-63.
10. Fronza M, Heinzmann B, Hamburger M, et al (2009). Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts. J Ethnopharmacol, 126, 463-7.
11. Gianni L, Eiermann W, Semiglazov V, et al (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84.
12. Graf C, Wessely N (2010). Physical activity in the prevention and therapy of breast cancer. Breast Care, 5, 389-94.
13. Hou A, Toh LX, Gan KH, et al (2013). Rho GTPases and regulation of cell migration and polarization in human corneal epithelial cells. PLoS One, 8, 77107.
14. Jozwiak J, Bikowska B, Grajkowska W, et al (2010). Activation of Akt/mTOR pathway in a patient with atypical teratoid/rhabdoid tumor. Folia Neuropathol, 48, 185-9.
15. Kostaras X, Cusano F, Kline GA, et al (2014). Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. Curr Oncol, 21, 493-503.
16. Kumagai H, Kusaba H, Okumura Y, et al (2014). Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan. Asian Pac J Cancer Prev, 15, 461-5.
17. Kurokawa M, Michelangeli VP, Findlay DM (1991). Induction of calcitonin receptor expression by glucocorticoids in T47D human breast cancer cells. J Endocrinol, 130, 321-6.
18. Liu L, Luo Y, Chen L, et al (2010). Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem, 285, 38362-73.
19. Lou YF, Zou ZZ, Chen PJ, et al (2014). Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One, 9, 97719.
20. Lu YS, Lien HC, Yeh PY, et al (2006a). Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer, 53, 303-10.
21. Lu YS, Lien HC, Yeh PY, et al (2005). Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World J Gastroenterol, 11, 6373-80.
22. Lu YS, Yeh PY, Chuang SE, et al (2006b). Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. J Endocrinol, 188, 311-9.
23. Nakayama Y, Ito Y, Tanabe M, et al (2013). A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study. Breast Cancer [Epub ahead of print].
24. Ono M, Kawakami M, Ushikubo H (1987). Stimulation of expression of the human endogenous retrovirus genome by female steroid hormones in human breast cancer cell line T47D. J Virol, 61, 2059-62.
25. Pal M, Koul S, Koul HK (2013). The transcription factor sterile alpha motif (SAM) pointed domain-containing ETS transcription factor (SPDEF) is required for E-cadherin expression in prostate cancer cells. J Biol Chem, 288, 12222-31.
26. Pandurangan AK (2013). Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev, 14, 2201-5.
27. Paplomata E, O'Regan R (2014). The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol, 6, 154-66.
28. Perlikos F, Harrington KJ, Syrigos KN (2013). Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol, 87, 1-11.
29. Polyak K (2011). Heterogeneity in breast cancer. J Clin Invest, 121, 3786-8.
30. Prat A, Perou CM (2011). Deconstructing the molecular portraits of breast cancer. Mol Oncol, 5, 5-23.
31. Sau S, Banerjee R (2014). Cationic lipid-conjugated dexamethasone as a selective antitumor agent. Eur J Med Chem, 83, 433-47.
32. Savarese A, Vecchione A (1993). Breast cancer heterogeneity assessed by flow cytometry. In Vivo, 7, 631-4.
33. Schmidt LJ, Duncan K, Yadav N, et al (2012). RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol, 26, 716-35.
34. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41.
35. Silva AS, Kam Y, Khin ZP, et al (2012). Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res, 72, 6362-70.
36. Sui JQ, Xie KP, Zou W, Xie MJ (2014). Emodin inhibits breast cancer cell proliferation through the ERalpha-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway. Asian Pac J Cancer Prev, 15, 6247-51.
37. Tsai WC, Tang FT, Wong MK, Pang JH (2003). Inhibition of tendon cell migration by dexamethasone is correlated with reduced alpha-smooth muscle actin gene expression: a potential mechanism of delayed tendon healing. J Orthop Res, 21, 265-71.
38. Turnbull C, Rahman N (2008). Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet, 9, 321-45.
39. Wang L, Yamaguchi S, Burstein MD, et al (2014). Novel somatic and germline mutations in intracranial germ cell tumours. Nature, 511, 241-5.
40. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22.
41. Xia X, Kar R, Gluhak-Heinrich J, et al (2010). Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res, 25, 2479-88.
42. Xing X, Zhang L, Wen X, et al (2014). PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs [Epub ahead of print].
43. Yamamoto T, Nishiguchi M, Inoue N, et al (2002). Inhibition of murine osteosarcoma cell proliferation by glucocorticoid. Anticancer Res, 22, 4151-6.
44. Yothaisong S, Dokduang H, Techasen A, et al (2013). Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol, 34, 3637-48.